Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 46-52

  Gertz, Morie A ^a   Ghobrial, Irene ^b   Luc Harousseau, Jean ^c  

^a Mayo Clinic   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; genetics; multiple myeloma; Stem Cell Transplantation

Indexed keywords

4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; AVN 944; BEZ 235; BORTEZOMIB; CP 51871; DEFOROLIMUS; DEHYDRODIDEMNIN B; DEXAMETHASONE; ENZASTAURIN; EVEROLIMUS; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PR 171; PREDNISONE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SCIO 469; SGN 40; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TKI 258; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG EXCRETION; DRUG MEGADOSE; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LOW DRUG DOSE; MICROENVIRONMENT; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMA CELL; PREVALENCE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 64749098712     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.10.006     Document Type: Article

References (42)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
2. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12 (2007) 131-144
3. Hideshima T., Podar K., Chauhan D., et al. Cytokines and signal transduction. Best Pract Res Clin Haematol 18 (2005) 509-524
4. Hwang J.J., Ghobrial I.M., and Anderson K.C. New frontiers in the treatment of multiple myeloma. ScientificWorldJournal 6 (2006) 1475-1503
5. Chng W.J., and Fonseca R. Genomics in multiple myeloma: biology and clinical implications. Pharmacogenomics 6 (2005) 563-573
6. Hideshima T., Bergsagel P.L., Kuehl W.M., et al. Advances in biology of multiple myeloma: clinical applications. Blood 104 (2004) 607-618
7. Hurt E.M., Wiestner A., Rosenwald A., et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5 (2004) 191-199
8. Bergsagel P.L., Kuehl W.M., Zhan F., et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106 (2005) 296-303
9. Roodman G.D. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17 (2002) 1921-1925
10. Aggarwal R., Ghobrial I.M., and Roodman G.D. Chemokines in multiple myeloma. Exp Hematol 34 (2006) 1289-1295
11. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
12. Dispenzieri A., Rajkumar S.V., Gertz M.A., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 82 (2007) 323-341
13. Cavo M., Patriarca F., Tacchetti P., et al. Bortezomib-thalidomide-dexamethasone vs. thalidomide-dexamethasone in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma (MM). Blood 110 (2007) abstract 73
14. Rajkumar S.V., Jacobus S., Callander N., et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome wi. J Clin Oncol 26 (2008) abstract 8504
15. Palumbo A., Bringhen S., Liberati A.M., Caravita T., Falcone A., Callea V., et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112 8 (2008 Oct 15) 3107-3114 Epub 2008 May 27
16. Weber D., Knight R., Chen C., et al. Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma. Blood 110 (2007) abstract 412
17. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 22 (2008) 1282-1284
18. San Miguel J.F., Schlag R., Khuageva N., et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 110 (2007) abstract 76
19. Hulin C., Virion J., Leleu X., et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo-controlled IFM 01-01 trial. J Clin Oncol 25 (2007) abstract 8001
20. Palumbo A., Falco P., Corradini P., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA, Italian Multiple Myeloma Network. J Clin Oncol 25 (2007) 4459-4465
21. Bahlis N.J., Song K., Trieu Y., et al. Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: results of the Canadian MM016 trial. Blood 110 (2007) abstract 3597
22. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47 (2007) 1466-1475
23. Roussou M., Kastritis E., Migkou M., et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49 (2008) 890-895
24. Harousseau J.L. Role of stem cell transplantation. Hematol Oncol Clin North Am 21 (2007) 1157-1174
25. Lokhorst H.M., Schmidt-Wolf I., Sonneveld P., et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93 (2008) 124-127
26. Morgan G.J., Davies F.E., and Owen R.G. Thalidomide combinations improve response rates: results from the MRC IX study. [abstract]. Blood 110 (2007) 1051
27. Harousseau J.-L., Mathiot C., and Attal M. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem-cell transplantation in previously untreated multiple myeloma: updated results from IFM 2005/01 trial. [abstract]. J Clin Oncol 26 (2008) 455
28. Cavo M., Patriarca F., and Tacchetti P. Bortezomib-thalidomide-dexamethasone vs. thalidomide-dexamethasone in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma. [abstract]. Blood 110 (2007) 30
29. Barlogie B., Pineda-Roman M., and Van Rhee F. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112 8 (2008 Oct 15) 3115-3121 Epub 2008 May 20
30. Pineda-Roman M., Zangari M., Haessler J., et al. Sustained complete remissions in multiple myeloma linked to bortezomib in Total Therapy 3: comparison with Total Therapy 2. Br J Haematol 140 (2008) 625-634
31. Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., et al. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 9513 (2006 Mar 11) 825-831
32. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 9 (2008 Aug 28) 906-917
33. Palumbo A., Falco P., Corradini P., Falcone A., Di Raimondo F., Giuliani N., et al. GIMEMA--Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol 25 28 (2007 Oct 1) 4459-4465 Epub 2007 Sep 4
34. Niesvizky R., Jayabalan D.S., Christos P.J., et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111 (2008) 1101-1109
35. Richardson P.G., Lonial S., Jakubowiak A., Jagannath S., Raje N., Avigan D., et al. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. J Clin Oncol 26 (2008) (May 20 suppl; abstr 8520)
36. Rajkumar S.V., Jacobus S., and Callander N. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma: a trial coordinated by the Eastern Cooperative Oncology Group. [abstract]. Blood 110 (2007) 31
37. Harousseau J.L. The allogeneic dilemma. Bone Marrow Transplant 40 (2007) 1123-1128
38. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
39. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
40. Rosinol L., Perez-Simon J.A., and Sureda A. A prospective PETHEMA study of tandem autologous transplant versus autograft followed by reduced-intensity conditioning allogeneic transplant in newly diagnosed multiple myeloma. Blood 112 8 (2008 Nov 1) 3591-3593 Epub 2008 Jul 8
41. Moreau P., Garban F., Attal M., Michallet M., Marit G., Hulin C., et al., IFM Group. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 112 9 (2008 Nov 1) 3914-3915
42. Rosiñol L., Pérez-Simón J.A., Sureda A., de la Rubia J., de Arriba F., Lahuerta J.J., et al. Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112 9 (2008 Nov 1) 3591-3593 Epub 2008 Jul 8